• Francesca Bagnato, Susan A Gauthier, Cornelia Laule, George R Wayne Moore, Riley Bove, Zhengxin Cai, Julien Cohen-Adad, Daniel M Harrison, Eric C Klawiter, Sarah A Morrow, Gülin Öz, William D Rooney, Seth A Smith, Peter A Calabresi, Roland G Henry, Jiwon Oh, Daniel Ontaneda, Daniel Pelletier, Daniel S Reich, Russell T Shinohara, Nancy L Sicotte, and NAIMS Cooperative.
• Neuroimaging Unit, Neuroimmunology Division, Department of Neurology, Vanderbilt University Medical Center, Nashville, TN.
• J Neuroimaging. 2020 May 1; 30 (3): 251-266.

AbstractClinicians involved with different aspects of the care of persons with multiple sclerosis (MS) and scientists with expertise on clinical and imaging techniques convened in Dallas, TX, USA on February 27, 2019 at a North American Imaging in Multiple Sclerosis Cooperative workshop meeting. The aim of the workshop was to discuss cardinal pathobiological mechanisms implicated in the progression of MS and novel imaging techniques, beyond brain atrophy, to unravel these pathologies. Indeed, although brain volume assessment demonstrates changes linked to disease progression, identifying the biological mechanisms leading up to that volume loss are key for understanding disease mechanisms. To this end, the workshop focused on the application of advanced magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging techniques to assess and measure disease progression in both the brain and the spinal cord. Clinical translation of quantitative MRI was recognized as of vital importance, although the need to maintain a relatively short acquisition time mandated by most radiology departments remains the major obstacle toward this effort. Regarding PET, the panel agreed upon its utility to identify ongoing pathological processes. However, due to costs, required expertise, and the use of ionizing radiation, PET was not considered to be a viable option for ongoing care of persons with MS. Collaborative efforts fostering robust study designs and imaging technique standardization across scanners and centers are needed to unravel disease mechanisms leading to progression and discovering medications halting neurodegeneration and/or promoting repair.© 2020 by the American Society of Neuroimaging.

21 keywords...

hide…